Complementary Table (Article Scoring)

Complementary Table											
Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Quality Score
Houzen	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	8/10
Hai Chen	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	NA	6/8
Xiao Liu	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9/10
Ma J.	Yes	Yes	Yes	Yes	No	No	Yes	No	NA	NA	5/8
Lau A.	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9/10
Karen Ribbons	Yes	Yes	No	No	Yes	Yes	Yes	Yes	NA	Yes	7/9
Shanthi Viswanathan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10/10
Ankit Singhal	Yes	Yes	Yes	Yes	No	Yes	Yes	No	NA	Yes	6/9
Eskandarieh Sharareh	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	9/9
Mousavizadeh A.	Yes	Yes	No	Yes	No	Yes	Yes	Yes	NA	Yes	7/9
Eskandarieh Sharareh	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	9/9
Eskandarieh Sharareh	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	9/9
Alroughani R.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10/10
Börü Ü.T.	Yes	Yes	No	No	Yes	Yes	Yes	Yes	NA	NA	6/8
Akdemir N.	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	NA	7/9
Nicoline Schiess	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	NA	Yes	8/9

Q1: Was the sample representative of the target population?
Q2: Were the participants recruited appropriately?
Q3: Was the sample size adequate?
Q4: Were the study subjects and setting described in detail?
Q5: Was data analysis conducted with the sufficient coverage of the identified samples?
Q6: Were objective and standard criteria used for the measurement of the condition?
Q7: Was the condition measured reliably?
Q8: Was there appropriate statistical analysis?
Q9: Were all the important confounding factors/subgroups/differences identified and accounted for?
Q10: Were subpopulations identified based on objective criteria?

	Ovid Embase Classic+Embase (2015-2018)	
	Search	*Results*
1.	Exp. Prevalence/	749,970
2.	Exp. Incidence/	937,837
3.	*Epidemiology/	234,816
4.	1 or 2 or 3	1,759,023
5.	Exp. Multiple Sclerosis/	103,368
6.	4 and 5	8,789
7.	Exp. Multiple Sclerosis/ep[Epidemiology]	71
8.	6 or 7	8,789
9.	limit 8 to yr="2015-Current"	71
10.	Limit 9 to animals	0
11.	9 not 10	25
12.	Exp. Japan/	32432
13.	11 and 12	3
14.	Exp. China/	59938
15.	11 and 14	1
16.	Exp. Korea/	17209
17.	11 and 16	1
18.	Exp. Hong Kong/	4902
19.	11 and 18	1
20.	Exp. Taiwan/	12788
21.	11 and 20	1
22.	Exp. Cambodia/	1313
23.	11 and 22	0
24.	Exp. Indonesia/	4400
25.	11 and 24	0
26.	Exp. Laos/	525
27.	11 and 26	0
28.	Exp. Malaysia/	5177
29.	11 and 28	1
30.	Exp. Thailand/	6470
31.	11 and 30	1
32.	Exp. Maldives/	77
33.	11 and 32	0
34.	Exp. Myanmar/	1114
35.	11 and 34	0
36.	Exp. Philippines/	280

37.	11 and 36	0
38.	Exp. Sri Lanka/	673
39.	11 and 38	1
40.	Exp. Thailand/	6470
41.	11 and 40	1
42.	Exp. Vietnam/	3569
43.	11 and 42	0
44.	Exp. Singapore/	5129
45.	11 and 44	0
46.	Exp. Brunei /	144
47.	11 and 46	0
48.	Exp. Bangladesh/	3835
49.	11 and 48	0
50.	Exp. Bhutan/	258
51.	11 and 50	0
52.	Exp. India/	32770
53.	11 and 52	1
54.	Exp. Nepal/	2826
55.	11 and 54	0
56.	Exp. Pakistan/	6583
57.	11 and 56	1
58.	Exp. Afghanistan/	1832
59.	11 and 58	0
60.	Exp. Bahrain	322
61.	11 and 60	0
62.	Exp. Iran/	16279
63.	11 and 62	2
64.	Exp. Iraq/	2056
65.	11 and 64	0
66.	Exp. Jordan/	1654
67.	11 and 66	0
68.	Exp. Kuwait/	903
69.	11 and 68	0
70.	Exp. Lebanon/	1255
71.	11 and 70	0
72.	Exp. Palestine/	402
73.	11 and 72	0
74.	Exp. Oman/	758
75.	11 and 74	0

76.		Exp. Qatar/	903
77.		11 and 76	0
78.		Exp. Saudi Arabia/	5136
79.		11 and 78	0
80.		Exp. Syria/	720
81.		11 and 80	0
82.		Exp. Tunisia/	1978
83.		11 and 82	0
84.		Exp. Turkey/	9882
85.		11 and 84	0
86.		Exp. United Arab Emirates/	661
87.		11 and 86	1
88.		Exp. Armenia/	323
89.		11 and 88	0
90.		Exp. Azerbaijan/	458
91.		11 and 90	0
92.		Exp. Georgia/	2030
93.		11 and 92	0
94.		Exp. Kazakhstan/	132
95.		11 and 94	0
96.		Exp. Kyrgyzstan/	222
97.		11 and 96	0
98.		Exp. Mongolia/	1251
99.		11 and 98	1
100.	5	Exp. Tajikistan/	169
101.	5	11 and 100	0
102.	5	Exp. Turkmenistan/	59
103.	6	11 and 102	0
104.	6	Exp. Uzbekistan/	289
105.	6	11 and 104	0
106.		Exp. Australia/	39,901
107.		11 and 106	7
108.		Exp. New Zealand/	83
109.		11 and 108	2

Total=26

Ovid MEDLINE (R) In-Process and Non-indexed Citation, Ovid MEDLINE (R) Daily, Ovid Medline (R), and Ovid OLDMEDLINE (R) (2015-2018)

	Search	*Results*
1.	Exp. prevalence/	256267
2.	Exp. incidence/	233138
3.	*epidemiology/	9648
4.	1 or 2 or 3	476726
5.	Exp. Multiple Sclerosis/	53199
6.	4 and 5	1627
7.	Exp. Multiple Sclerosis/ep[Epidemiology]	4411
8.	6 or 7	4816
9.	limit 8 to yr="2015-Current"	766
10.	limit 9 to animals	17
11.	9 not 10	749
12.	Exp. Japan/	122526
13.	11 and 12	8
14.	Exp. China/	153568
15.	11 and 14	9
16.	Exp. Korea/	38204
17.	11 and 16	2
18.	Exp. Hong Kong/	13840
19.	11 and 18	1
20.	Exp. Taiwan/	32602
21.	11 and 20	7
22.	Exp. Cambodia/	2906
23.	11 and 22	0
24.	Exp. Indonesia/	8977
25.	11 and 24	0
26.	Exp. Laos/	1679
27.	11 and 26	0
28.	Exp. Malaysia/	13258
29.	11 and 28	0
30.	Exp. Thailand/	24133
31.	11 and 30	0
32.	Exp. Maldives/	10547
33.	11 and 32	0
34.	Exp. Myanmar/	1964
35.	11 and 34	0
36.	Exp. Philippines/	7682
37.	11 and 36	0

38.	Exp. Sri Lanka/	5310
39.	11 and 38	0
40.	Exp. Thailand	24113
41.	11 and 40	0
42.	Exp. Vietnam/	10832
43.	11 and 42	0
44.	Exp. Singapore/	11571
45.	11 and 44	0
46.	Exp. Brunei /	178
47.	11 and 46	0
48.	Exp. Bangladesh/	9211
49.	11 and 48	0
50.	Exp. Bhutan/	361
51.	11 and 50	0
52.	Exp. India/	92831
53.	11 and 52	6
54.	Exp. Nepal/	6782
55.	11 and 54	0
56.	Exp. Pakistan/	14680
57.	11 and 56	0
58.	Exp. Afghanistan/	2899
59.	11 and 58	1
60.	Exp. Bahrain	538
61.	11 and 60	0
62.	Exp. Iran/	21569
63.	11 and 62	23
64.	Exp. Iraq/	4259
65.	11 and 64	0
66.	Exp. Jordan/	3569
67.	11 and 66	0
68.	Exp. Kuwait/	2802
69.	11 and 68	9
70.	Exp. Lebanon/	3681
71.	11 and 70	2
72.	Exp. Palestine/	26998
73.	11 and 72	1
74.	Exp. Oman/	1223
75.	11 and 74	1
76.	Exp. Qatar/	899

77.		11 and 76	0
78.		Exp. Saudi Arabia/	11088
79.		11 and 78	0
80.		Exp. Syria/	1444
81.		11 and 80	0
82.		Exp. Tunisia/	7350
83.		11 and 82	4
84.		Exp. Turkey/	30566
85.		11 and 84	0
86.		Exp. United Arab Emirates/	1727
87.		11 and 86	2
88.		Exp. Armenia/	1303
89.		11 and 88	0
90.		Exp. Azerbaijan/	1145
91.		11 and 90	0
92.		Exp. Georgia/	9958
93.		11 and 92	1
94.		Exp. Kazakhstan/	2431
95.		11 and 94	0
96.		Exp. Kyrgyzstan/	1210
97.		11 and 96	0
98.		Exp. Mongolia/	1569
99.		11 and 98	0
100.	5	Exp. Tajikistan/	693
101.	٥	11 and 100	0
102.	٥	Exp. Turkmenistan/	559
103.	6	11 and 102	0
104.	6	Exp. Uzbekistan/	1855
105.	6	11 and 104	0
106.		Exp. Australia/	129178
107.		11 and 106	10
108.		Exp. New Zealand/	3609
109.		11 and 108	5

Total=92